Pharmaceutical and Biological Evaluations最新文献_第3页

Assay comparison of rivaroxaban by new HPLC method with an existing method in tablet dosage form 利伐沙班片剂剂型HPLC测定方法与现有方法的比较

Pharmaceutical and Biological Evaluations Pub Date : 2017-06-01 DOI: 10.26510/2394-0859.PBE.2017.27

S. Sahoo, S. K. Mekap

{"title":"Assay comparison of rivaroxaban by new HPLC method with an existing method in tablet dosage form","authors":"S. Sahoo, S. K. Mekap","doi":"10.26510/2394-0859.PBE.2017.27","DOIUrl":"https://doi.org/10.26510/2394-0859.PBE.2017.27","url":null,"abstract":"Objective: In the present work, RP-HPLC procedure is optimized to finalize a different approach for the estimation of rivaroxaban in tablet dosage form. A novel drug rivaroxaban used as anti-coagulant in the patients for the prevention of thromboembolism. Methods: The molecule is identified with the molar mass of 435.882 g/mol and molecular formula C 19 H 18 ClN 3 O 5 S. The determination was executed by C18 column (Phenomenex 250 x 4.6 mm, 5 μm maintained at 35°C) at 251 nm with a mobile phase (ACN: Water, 55:45 v/v) and flow of 1.2 ml/min. Results: The retention time found to be about 3.8minutes.The validation parameters performed as per ICH guidelines and found to be within acceptance criteria. Linearity of the method is found to be accepted across five concentration level i.e. being studied by calibration curve. Accuracy was executed at three different concentrations, the amount being recovered are close to 100%. The % RSD values obtained for repeatability, intermediate and reproducibility under precision are within acceptance criteria. Conclusions: The method was accurate, precise, robust and rapid for quantitative determination of rivaroxaban by High Performance Liquid Chromatography.","PeriodicalId":19998,"journal":{"name":"Pharmaceutical and Biological Evaluations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86288980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Understanding Bell's palsy –a review 理解贝尔的麻痹——回顾

Pharmaceutical and Biological Evaluations Pub Date : 2017-06-01 DOI: 10.26510/2394-0859.pbe.2017.20

B. Prabasheela, V. Sakithya, V. Nandhini, M. Logeshwari

引用次数: 4

Recent advances in Parkinson disease 帕金森病的最新进展

Pharmaceutical and Biological Evaluations Pub Date : 2017-06-01 DOI: 10.26510/2394-0859.PBE.2017.22

S. Chandra, M. Srivastav, N. Chauhan

{"title":"Recent advances in Parkinson disease","authors":"S. Chandra, M. Srivastav, N. Chauhan","doi":"10.26510/2394-0859.PBE.2017.22","DOIUrl":"https://doi.org/10.26510/2394-0859.PBE.2017.22","url":null,"abstract":"The article reviewed various therapies other than dopamine treatment like A2a antagonists: antiparkinson medication reducing the over reactivity of substantia nigra due to loss of dopamine; Levodopa/Carbidopa Intestinal Gel: an aqueous gel containing levodopa and carbidopa; stem-cell therapies like embryonic and adult stem cell can be act through several mechanism; acupuncture: reduced the motor symptoms and other disease related factors; various antiparkinson medications like IPX066 and ND0611 are sustained release and transdermal patches which are transported to GIT through high nutrients and patches are found to be useful in increasing the concentration, half-life of levodopa, thus downs the threatening risk of PD. The future treatment for PD should be considered as they have less side-effect and better results than other treatment as they not only decrease the symptoms but also the incidences of PD. If the symptoms are diagnosed early patient should go for genetic therapy to relieve from the disease which not only reduce the progressive increase of symptoms and disease. Considering all therapies, future treatments shows the weightage in reducing the progressive increase of PD in patient. Though these treatments are proven to be effective in treatment but still more targeted tools and techniques are required which can specifically target the cause and thus lowers the graph and rating scale of PD.","PeriodicalId":19998,"journal":{"name":"Pharmaceutical and Biological Evaluations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77936796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advance approaches in alopecia 脱发的先进方法

Pharmaceutical and Biological Evaluations Pub Date : 2017-06-01 DOI: 10.26510/2394-0859.PBE.2017.21

A. Mohan, M. Khan, S. Chandra

引用次数: 4

Comparative studies on the antibacterial activities of leaf extracts of Azadirachta indica and Psidium guajava and antibiotics on methicillin and vancomycin resistant Staphylococcus aureus 印楝叶提取物与番石榴叶提取物与抗生素对耐甲氧西林、万古霉素金黄色葡萄球菌抑菌活性的比较研究

Pharmaceutical and Biological Evaluations Pub Date : 2017-06-01 DOI: 10.26510/2394-0859.PBE.2017.24

Eze Cj, I. Iroha, S. C. Eluu, P. C. Ejikeugwu, C. Iroha, M. Ajah, E. Nwakaeze, E. Ugwu

{"title":"Comparative studies on the antibacterial activities of leaf extracts of Azadirachta indica and Psidium guajava and antibiotics on methicillin and vancomycin resistant Staphylococcus aureus","authors":"Eze Cj, I. Iroha, S. C. Eluu, P. C. Ejikeugwu, C. Iroha, M. Ajah, E. Nwakaeze, E. Ugwu","doi":"10.26510/2394-0859.PBE.2017.24","DOIUrl":"https://doi.org/10.26510/2394-0859.PBE.2017.24","url":null,"abstract":"Objective: This study investigated the antibacterial activity of the acetone, methanol, and ethanol leaf extracts of Azadirachta indica and Psidium guajava against methicillin resistant Staphylococcus aureus ( MRSA) and vancomycin resistant Staphylococcus aureus (VRSA) strains as well as the antimicrobial activity of some conventional antibiotics on these multidrug resistant organisms. Methods: MRSA and VRSA strains were obtained from the culture collection unit of a tertiary hospital in Ebonyi State, Nigeria. The test organisms and the plant extracts were processed using standard microbiology techniques. Kirby-Bauer disk diffusion technique was used to determine the antimicrobial susceptibility profile of the MRSA and VRSA strains to some conventionally used antibiotics; and the antibacterial activity of the plant extracts was evaluated using agar well diffusion technique with three solvents: ethanol, methanol and acetone. Results: It was revealed in this study that the extracts of A. indica and P. guajava demonstrated some level of antimicrobial activity against the test organism at concentrations of 100 mg/ml and 50 mg/ml. Compared to the conventional antibiotics used, the antibiotics showed better antimicrobial activity against the test organisms than the plant extracts which was least active against the MRSA and VRSA strains. Conclusions: Though the A. indica and P. guajava extracts showed some appreciable antimicrobial activity against the MRSA and VRSA strains, the conventional antibiotics produced better antimicrobial action against these multidrug resistant bacteria. The search for novel compounds with putative antimicrobial activity should be stepped up since plants holds the potential for discovering novel drugs.","PeriodicalId":19998,"journal":{"name":"Pharmaceutical and Biological Evaluations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89146132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Formulation and evaluation of orodispersible tablet of ivabradine hydrochloride 盐酸伊伐布雷定口腔分散片的研制与评价

Pharmaceutical and Biological Evaluations Pub Date : 2017-06-01 DOI: 10.26510/2394-0859.pbe.2017.25

D. Patel, K. Patel, P. Bharadia

{"title":"Formulation and evaluation of orodispersible tablet of ivabradine hydrochloride","authors":"D. Patel, K. Patel, P. Bharadia","doi":"10.26510/2394-0859.pbe.2017.25","DOIUrl":"https://doi.org/10.26510/2394-0859.pbe.2017.25","url":null,"abstract":"Objective: The objective of present research work was to develop formulation of orodispersible tablets of Ivabradine HCl and evaluate it for different evaluation parameters. Methods: The tablets were prepared by direct compression method. The formulation of the tablets were evaluated before compression for characterization of flow properties and after compression for different parameters of orodispersible tablet formulation. Results: Ivabradine hydrochloride orodispersible tablets were developed with considerable increase in drug release as compared to marketed formulations; nine formulations were developed and studied. The difference in drug release values was found to be 100.88 ± 0.10 respectively. The drug was characterized according to different compendial methods, on the basis of identification by HPLC, pH, organoleptic properties and other tests. Parameters evaluated were within prescribed limits and indicated good free flowing properties. The F6 batch with disintegration time 21 ± 3.0 and dissolution 99.29% was selected as optimized formulation. This was compared with conventional marketed formulation and was found superior. Batch F6 was also subjected to stability studies for two months and was tested for its hardness, wetting time, disintegration time, drug contents and dissolution behaviour monthly. Conclusions: By appropriate selection of excipients, it was possible to develop orodispersible tablets of Ivabradine HCl.","PeriodicalId":19998,"journal":{"name":"Pharmaceutical and Biological Evaluations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78490506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Lysine specific demethylase 1 as therapeutic target of cancer 赖氨酸特异性去甲基酶1作为癌症的治疗靶点

Pharmaceutical and Biological Evaluations Pub Date : 2017-06-01 DOI: 10.26510/2394-0859.PBE.2017.23

N. Panda, S. Bhoi, R. Rawal, M. K. Raval

引用次数: 0

Antifungal potential of improved crude extracts of Mitracarpus scaber (Zucc) against Candida guilliermondii and Candida parapsilosis 米特拉卡普斯(Zucc)改良粗提物对吉列蒙假丝酵母和副假丝酵母的抑菌作用

Pharmaceutical and Biological Evaluations Pub Date : 2017-04-02 DOI: 10.26510/2394-0859.PBE.2017.14

E. K. Kporou, C. Ibourahema, A. J. Ackah, S. Ouattara

{"title":"Antifungal potential of improved crude extracts of Mitracarpus scaber (Zucc) against Candida guilliermondii and Candida parapsilosis","authors":"E. K. Kporou, C. Ibourahema, A. J. Ackah, S. Ouattara","doi":"10.26510/2394-0859.PBE.2017.14","DOIUrl":"https://doi.org/10.26510/2394-0859.PBE.2017.14","url":null,"abstract":"Objective: The present study was undertaken to evaluate antifungal potential of improved crude extracts of Mitracarpus scaber Zucc., an ivorian traditional medicinal plant against two species of clinical yeast isolates: Candida parapsilosis and Candida guilliermondii . Methods : For evaluation of antifungal activity, double dilution method in slope tubes was used. Crude extracts of M . scaber were prepared by extracting with a blender in aqueous and hydroalcohol. In first; Aqueous (X Aq ) and Hydroalcoholic (X 0 ) extracts were evaluated, and secondary the crude extract X 0 was improved by partition in mixture of aqueous and hexanic solvent 50:50 v/v. Each dried phase was also examined. A phytochemical screening has been performed on most active extracts. Results : In vitro antifungal activity showed that crude extract X 0 was the most active with MIC = 6.25 mg/ml. Among the extracts obtained by partition from extract X 0 , extract X 11 (Hexanic phase) was the better with lowest antifungal parameters MIC and MFC range between 1.562 mg/ml and 0.781 mg/ml and IC 50 range between 0.73 mg/ml to 0.598 mg/ml. In addition, the most active extract contained only terpens and steroids. Conclusions : Antifungal activity of M . scaber was improved by partition of an hydroalcoholic extract (X 0 ) in mixture hexane-water 50:50 v/v. Hexanic phase (X 11 ) was more active against C . parapsilosis and C . guilliermondii .","PeriodicalId":19998,"journal":{"name":"Pharmaceutical and Biological Evaluations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76881506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Structure based screening of ligands against dTDP-6-deoxy-D-xylo-4-hexulose 3, 5-epimerase (RmlC): phytochemical as drug candidate for Mycobacterium tuberculosis 基于结构的抗dtdp -6-脱氧-d -木质素-4-己糖3,5 - epimase (RmlC)配体筛选:作为结核分枝杆菌候选药物的植物化学

Pharmaceutical and Biological Evaluations Pub Date : 2017-04-02 DOI: 10.26510/2394-0859.pbe.2017.15

J. Rath, M. K. Raval

引用次数: 1

Design and characterization of metoprolol floating matrix tablet 美托洛尔漂浮基质片的设计与表征

Pharmaceutical and Biological Evaluations Pub Date : 2017-04-02 DOI: 10.26510/2394-0859.PBE.2017.18

V. Bakshi, .S Swapna, D. Choudhary, C. Revanth, B. Praveen, C. Praveen

{"title":"Design and characterization of metoprolol floating matrix tablet","authors":"V. Bakshi, .S Swapna, D. Choudhary, C. Revanth, B. Praveen, C. Praveen","doi":"10.26510/2394-0859.PBE.2017.18","DOIUrl":"https://doi.org/10.26510/2394-0859.PBE.2017.18","url":null,"abstract":"Objective: The objective of the present research was to develop a matrix embedded floating tablet of Metoprolol for the sustained activity and prolongation of gastric residence time to improve the bioavailability of the drug. Metoprolol was chosen as a model drug because it is better absorbed in the stomach than the lower gastro intestinal tract. Methods: The experimental work was divided into pre-formulation studies, formulation development, and evaluation. Standardization of drug and excipients confirmed the authentication of the samples. Floating test were conducted for all formulations, In vitro dissolution studies were carried out in a dissolution testing apparatus-II, FTIR study was performed to interpret the drug ,excipient interaction. Results: Floating tests were also performed for 15 formulations and among them five formulations have passed the floating tests (F1, F3, F5, F7, and F14). The In-vitro release kinetics study of this tablet indicated sustained release for Metoprolol and followed zero order release and 95% drug in 8 h in vitro . The drug release profile of formulated product was compared with marketed product Metolar. The floating tablets extended the drug release up to 8 hours. The drug-polymer interaction was evaluated by fourier transform infrared spectroscopy (FTIR). Conclusions: F3 formulation showed the best floating results. The comparative study between F3 and Metolar (Marketed Product) showed the similar in vitro drug release profile. Thus, the optimzed formulation F-3 can be successfully used for the management of hypertension.","PeriodicalId":19998,"journal":{"name":"Pharmaceutical and Biological Evaluations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79031872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0